See other companies on Otta
Kheiron Medical
AI enhanced cancer detection tools for radiologists
- 21-100 employees
- Healthcare
- B2B
- Artificial Intelligence
- Deep Tech
- Biology
- Data Analysis
- Stylus Building, 2nd Floor, 112-116 Old St, London, United Kingdom,
Jump to section
Company mission
To give patients a better fighting chance against cancer using deep learning technology that works with radiologists.
Insights
Otta's take
Sam Franklin
CEO of Otta
Kheiron is a medical technology company that uses advanced machine learning to develop and deliver intelligent tools for radiologists, radiology departments, imaging centres and hospitals. Its tools and services improve the efficiency, consistency and accuracy of radiology reporting.
The company has made significant breakthroughs with its breast cancer screening product, Mia, but this was just the beginning of its journey. According to external clinical trial results, Kheiron’s deep learning technology achieves state-of-the-art malignancy detection support in breast cancer screening.
Ultimately Kheiron wants to radically improve the outcomes for cancer patients by pioneering a new era of, what they call, precision radiology.
Benefits
- Mental health support through Spill
- Extended parental leave
- Cycle to work scheme
- Equity to make you a partner in our commercial success
- Work from home opportunities
- Health insurance
Company values
- Strive for the extraordinary
- Have a bias to action
- Be curious to learn from each other
- Embrace a growth mindset
- Speak your mind with respect
- Hold strong opinions weakly
Funding (last 2 of 3 rounds)
Jul 2019
$21.5m
SERIES A
Oct 2018
$0.1m
GRANT
$34.1m
Total funding
This company has top investors
Founders
Peter Kecskemethy
(CEO)Previously PhD Researcher at University of Oxford for 6 years and Teaching Assistant at University of Reading for 1 year.
Tobias Rijken
(CTO)Previously Founding Director at The Young Consultant for 1 year and Co-founder & Head of Data Science at 42 Education.
People progressing
Annie
Joined as Compliance and Clinical Operations Lead, being promoted to Product Manager after 2 years. After another year and 3 months became a Senior Scientist. As of April 2023 she has been promoted to Science Lead.
Articles
